{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:52:06Z","timestamp":1780631526606,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.anl.2022.02.006","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T15:26:39Z","timestamp":1645889199000},"page":"834-844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-5877","authenticated-orcid":false,"given":"Shuya","family":"Otsuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9856-7157","authenticated-orcid":false,"given":"Ryusuke","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-2091","authenticated-orcid":false,"given":"Shogo","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-8161","authenticated-orcid":false,"given":"Tsuyoshi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanobu","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Asato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morimasa","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Ichimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Kitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kumabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tsujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ushiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3404-5461","authenticated-orcid":false,"given":"Koichi","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2022.02.006_bib0001","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2022.02.006_bib0002","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.oraloncology.2017.07.023","article-title":"A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141","volume":"73","author":"Kiyota","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0003","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/hed.26331","article-title":"Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)","volume":"42","author":"Yen","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2022.02.006_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091317","article-title":"Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma","volume":"11","author":"Hori","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.anl.2022.02.006_bib0005","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.anl.2022.02.006_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12113427","article-title":"Real-world, long-term outcomes of nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck and impact of the magnitude of best overall response: A retrospective multicenter study of 88 patients","volume":"12","author":"Matsuki","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.anl.2022.02.006_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2019.104525","article-title":"Relationship between immune-related adverse events and the long-term outcomes in recurrent\/metastatic head and neck squamous cell carcinoma treated with nivolumab","volume":"101","author":"Matsuo","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0009","article-title":"Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study","author":"Hanai","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0012","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0013","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anl.2022.02.006_bib0014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2017.11.015","article-title":"Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data","volume":"126","author":"Dudnik","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.anl.2022.02.006_bib0015","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/00016489.2020.1807601","article-title":"Clinical outcome in recurrent and\/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events","volume":"140","author":"Yasumatsu","year":"2020","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.anl.2022.02.006_bib0016","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00405-020-05945-5","article-title":"Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma\u00a0: prognostic value of combined performance status and modified Glasgow prognostic score","volume":"277","author":"Ueki","year":"2020","journal-title":"Eur Arch Oto-Rhino-Laryngology"},{"key":"10.1016\/j.anl.2022.02.006_bib0017","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s12094-017-1829-5","article-title":"Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients","volume":"20","author":"Garde-Noguera","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors \u2013 A systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.anl.2022.02.006_bib0019","first-page":"1","article-title":"Correlation between patients\u2019 age and cancer immunotherapy efficacy","volume":"8","author":"Wu","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.anl.2022.02.006_bib0020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/ajco.13374","article-title":"Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study","volume":"16","author":"Kondo","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0021","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2019.08.026","article-title":"Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck","volume":"121","author":"Saleh","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anl.2022.02.006_bib0022","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.anl.2019.05.001","article-title":"Outcome of chemotherapy following nivolumab treatment for recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"47","author":"Wakasaki","year":"2020","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.anl.2022.02.006_bib0023","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3390\/cancers12082299","article-title":"Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"12","author":"Wakasaki","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.anl.2022.02.006_bib0024","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non\u2013small cell lung cancer","volume":"13","author":"Park","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0025","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1159\/000507219","article-title":"Response rate and prognostic impact of salvage chemotherapy after nivolumab in patients with advanced gastric cancer","volume":"98","author":"Arigami","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.anl.2022.02.006_bib0026","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1200\/JCO.2020.38.15_suppl.6532","article-title":"HANNA: Real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany","volume":"38","author":"Dietz","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814622000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814622000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:39:44Z","timestamp":1759952384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814622000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0385814622000384"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2022.02.006","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2022.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}